EUVIMEDEUVIMED entdecken
Crossref

Discovery of natural product-derived rosavin as a programmed death-ligand 1 inhibitor for cancer immunotherapy

Wei Zou, Tianle Li, Jacek Plewka, Xiaoxiong Song, Xueting Wan, Xin Luo, Mengyuan Gao, Suyun Yu, Yuanyuan Wu, Xiaoman Li, Aiyun Wang, Katarzyna Magiera-Mularz und 5 weitere

Phytomedicine · 2026-09 · 159 · 158609

DOI: 10.1016/j.phymed.2026.158609 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2026-09. Verfasst von Wei Zou und 16 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu key Laboratory for Pharmacology and Safety Research of Chinese Materia Mediea, School of Pharmacy, Nanjing University of Chinese Medicine, Na…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Immunotherapy, Biological Products, Immune Checkpoint Inhibitors. Die Arbeit nennt 72 Literaturangaben. Gefördert von: Jiangsu Province Natural Science Foundation, National Science Centre Poland, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Given the limitations of the existing monoclonal antibody (mAb)-based therapies, more efficient and safer small-molecule-based checkpoint therapies targeting the programmed cell death-1 (PD-1) / programmed cell death ligand-1 (PD-L1) axis are gaining growing attention and urgently required. OBJECTIVE To identify a novel PD-L1 small-molecule inhibitor from natural products and systematically evaluate its antitumor activity, mechanism of action, and potential biomarkers. METHODS Based on the co-crystal structure of PD-L1 with BMS-202 (PDB ID: 5J89), molecular docking was employed for high-throughput virtual screening of 16,563 natural products. The binding affinity of candidate compounds to PD-L1 protein was validated through microscale thermophoresis (MST), cellular thermal shift assay (CETSA), drug affinity responsive target stability (DARTS) assays and nuclear magnetic resonance (NMR). The blockade of PD-1/PD-L1 interaction was assessed using homogeneous time-resolved fluorescence (HTRF), NFAT-Luc luciferase reporter gene system, and cell membrane PD-1 binding assays. In vivo antitumor efficacy was systematically assessed in humanized PD-L1 knock-in B16F10 and MC38 tumor-bearing mouse models. The mechanism of action was investigated using RNA-seq transcriptomics, flow cytometry, and immunofluorescence staining. Finally, response mechanisms and potential biomarkers were systematically analyzed by comparing differential responses across distinct tumor models. RESULTS Through high-throughput virtual screening, we identified rosavin as a small molecule with a novel scaffold that targets PD-L1, exhibiting the unusual small-molecule property of inhibiting PD-L1 without inducing its dimerization. Rosavin demonstrated significant antitumor activity in vivo by promoting antitumor immunity through enhancing CD8+ T cell activation, consistent with the effects of PD-L1/PD-1 blockade. Notably, rosavin was particularly effective for fighting against tumor progression in microsatellite instability-high (MSI-H) solid tumors and robustly strengthened the expression levels of CXCL9 and CXCL10 in tumors, which may serve as potential biomarkers for predicting responsiveness to rosavin-mediated PD-1/PD-L1 blockade. CONCLUSION Rosavin serves as a privileged novel and unexpected scaffold for designing potent PD-1/PD-L1 modulators, offering promising candidates for cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenImmunotherapyBiological ProductsImmune Checkpoint InhibitorsNeoplasmsAnimalsHumansMiceMolecular Docking SimulationCell Line, TumorProgrammed Cell Death 1 ReceptorFemaleAcetamidesPyridines

Stichwörter der Autor:innen

CXCL9/CXCL10Cancer immunotherapyMSI-H solid tumorsPD-1/PD-L1RosavinSmall-molecule inhibitor

Substanzen

B7-H1 AntigenBiological ProductsProgrammed Cell Death 1 ReceptorCD274 protein, humanBMS202Immune Checkpoint InhibitorsAcetamidesPyridines

Autor:innen und Institutionen

  • Jiangsu key Laboratory for Pharmacology and Safety Research of Chinese Materia Mediea, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Jiangsu Joint International Research Laboratory…
  • Jiangsu key Laboratory for Pharmacology and Safety Research of Chinese Materia Mediea, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Krakow, Poland.
  • Department of Biochemistry and Molecular Biology, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Jiangsu Joint International Research Laboratory of Chinese Medicine and Regenerative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Department of Biochemistry and Molecular Biology, School of…
  • Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, CA, 92093-0204, USA.

Förderung

  • Jiangsu Province Natural Science Foundation
  • National Science Centre Poland
  • National Natural Science Foundation of China
  • Natural Science Research of Jiangsu Higher Education Institutions of China

Zitieren

APA

Zou, W., Li, T., Plewka, J., Song, X., Wan, X., Luo, X., Gao, M., Yu, S., Wu, Y., Li, X., Wang, A., Magiera-Mularz, K., Musielak, B., Fenical, W., Zhao, Y., Wei, Z., & Lu, Y. (2026). Discovery of natural product-derived rosavin as a programmed death-ligand 1 inhibitor for cancer immunotherapy. Phytomedicine, 159, 158609. https://doi.org/10.1016/j.phymed.2026.158609

Vancouver

Zou W, Li T, Plewka J, Song X, Wan X, Luo X, et al. Discovery of natural product-derived rosavin as a programmed death-ligand 1 inhibitor for cancer immunotherapy. Phytomedicine. 2026;159:158609. doi:10.1016/j.phymed.2026.158609

BibTeX
@article{Zou2026,
  author = {Zou, Wei and Li, Tianle and Plewka, Jacek and Song, Xiaoxiong and Wan, Xueting and Luo, Xin and Gao, Mengyuan and Yu, Suyun and Wu, Yuanyuan and Li, Xiaoman and Wang, Aiyun and Magiera-Mularz, Katarzyna and Musielak, Bogdan and Fenical, William and Zhao, Yang and Wei, Zhonghong and Lu, Yin},
  title = {Discovery of natural product-derived rosavin as a programmed death-ligand 1 inhibitor for cancer immunotherapy},
  journal = {Phytomedicine},
  year = {2026},
  volume = {159},
  pages = {158609},
  doi = {10.1016/j.phymed.2026.158609}
}
Kostenlos starten →